{
    "clinical_study": {
        "@rank": "57088", 
        "arm_group": [
            {
                "arm_group_label": "EV71 Vaccine", 
                "description": "Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo in 5000 infants aged 6-35 months old on day0,28"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum samples will be taken from 1200 subjects in the immunogenicity subgroup 26 months\n      after the first vaccination.\n\n      Throat and anal swab samples will be taken from the cases with Hand, Foot and mouth disease\n      for the detection of PCR assays and the isolation of EV71."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this follow-up study is to evaluate the two-year efficacy, immunogenicity and\n      safety of EV71 Vaccines in preventing Hand, Foot and Mouth disease caused by EV71 in a total\n      10,000 healthy infants volunteers aged from 6 to 35months old."
        }, 
        "brief_title": "A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hand, Foot and Mouth Disease", 
        "condition_browse": {
            "mesh_term": [
                "Enterovirus Infections", 
                "Foot-and-Mouth Disease", 
                "Hand, Foot and Mouth Disease", 
                "Mouth Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The phase III, efficacy trial of inactivated vaccine (vero cell) against EV71 has completed\n      on March 2013 in China. The data from the phase III study suggested that the inactivated\n      EV71 vaccine had protection effects on healthy Chinese infants against  Hand, Foot and Mouth\n      disease caused by EV71 within one-year surveillance period, and had clinically acceptable\n      safety and good one-year immune persistence.\n\n      This study is the phase III, open-labelled, follow-up research, in order to evaluate the\n      two-year efficacy, safety and immune persistence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All subjects vaccinated at least one injection of EV71 vaccine or the placebo in the\n             phase III efficacy trial.\n\n        Exclusion Criteria:\n\n          -  subjects who refuse to continue in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Months", 
            "minimum_age": "6 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Healthy Chinese infants aged 6 to 35 months old"
            }
        }, 
        "enrollment": {
            "#text": "10077", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001233", 
            "org_study_id": "PRO-EV71-3003"
        }, 
        "intervention": {
            "arm_group_label": "EV71 Vaccine", 
            "description": "inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval", 
            "intervention_name": "EV71 vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EV71 vaccine", 
            "EV71-associated HFMD", 
            "efficacy", 
            "safety", 
            "immune persistence"
        ], 
        "lastchanged_date": "November 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lianyungang", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "222100"
                    }, 
                    "name": "Ganyu"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taizhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "225400"
                    }, 
                    "name": "Taixing"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yancheng", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "224300"
                    }, 
                    "name": "Sheyang"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine", 
        "overall_official": {
            "affiliation": "Jiangsu Center for Diseases Control and Prevention", 
            "last_name": "Feng-Cai Zhu, BS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to evaluate the efficacy of EV71 vacccine against HFMD caused by EV71", 
            "measure": "The incidence rate of Hand, Foot and Mouth disease caused by EV71 within the second year observation period after the second vaccination", 
            "safety_issue": "No", 
            "time_frame": "Within the second year after the second vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to evaluate the immune persistence of anti-EV71 antibodies in serum", 
                "measure": "The GMT of anti-EV71 antibodies in serum two years after second vaccination", 
                "safety_issue": "No", 
                "time_frame": "26  months after second vaccination"
            }, 
            {
                "description": "Frequency of serious adverse events in healthy infants during the oney-year follow-up period", 
                "measure": "Frequency of serious adverse events (SAEs) with the second year after the second vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "within the second year after the second vaccination"
            }
        ], 
        "source": "Sinovac Biotech Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sinovac Biotech Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}